Analysts Set Savara Inc (NASDAQ:SVRA) PT at $11.17

Shares of Savara Inc (NASDAQ:SVRA) have been given an average rating of “Moderate Buy” by the six research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $10.17.

A number of equities research analysts have weighed in on SVRA shares. HC Wainwright decreased their target price on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday. JMP Securities restated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. Finally, Evercore ISI reiterated an “in-line” rating and set a $5.00 target price (down from $7.00) on shares of Savara in a report on Wednesday.

Savara Trading Down 6.6 %

Shares of SVRA opened at $2.98 on Tuesday. The firm has a market capitalization of $511.43 million, a price-to-earnings ratio of -6.93 and a beta of 1.02. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 11.31. Savara has a 1-year low of $2.83 and a 1-year high of $5.70. The company has a 50-day moving average of $3.88 and a 200 day moving average of $4.19.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). On average, research analysts expect that Savara will post -0.44 EPS for the current year.

Institutional Investors Weigh In On Savara

A number of hedge funds have recently made changes to their positions in SVRA. ProShare Advisors LLC grew its stake in Savara by 9.0% in the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock valued at $128,000 after purchasing an additional 2,114 shares during the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Savara by 9.0% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 44,956 shares of the company’s stock worth $191,000 after buying an additional 3,706 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Savara by 15.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 33,692 shares of the company’s stock worth $168,000 after acquiring an additional 4,625 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Savara by 14.9% during the second quarter. The Manufacturers Life Insurance Company now owns 41,250 shares of the company’s stock valued at $166,000 after acquiring an additional 5,335 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Savara by 5.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 125,815 shares of the company’s stock valued at $533,000 after acquiring an additional 6,141 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.